Akari Therapeutics, Plc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Abizer Gaslightwala
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 401 East Jackson Street Tampa FL United States of America 33602
- IPO Date
- Jan 6, 2014
- CIK
- 0001541157
- Website
- akaritx.com
- Similar Companies
- Business
- Akari Therapeutics, Plc (NASDAQ: AKTX) is a London-based clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology, leveraging proprietary cancer-killing toxin payloads to enhance efficacy and safety in cancer therapies. The company offers a pipeline centered on precision bifunctional ADCs, including its lead product candidate AKTX-101, a preclinical-stage Trop2-targeting ADC that combines the novel PH1 payload—which disrupts spliceosome function and triggers immune responses—with a Trop2 antibody for treating solid tumors such as lung, breast, colon, and prostate cancers; additional preclinical assets target other tumor antigens using this discovery engine. Akari operates primarily in the United States and United Kingdom, with headquarters at 75-76 Wimpole Street in London, W1G 9RT, UK, and U.S. offices in New York and Boston. Founded prior to its public listing, the company serves pharmaceutical partners and patients in the oncology and autoinflammatory disease segments through targeted therapies addressing unmet needs in solid tumors and immune-mediated conditions. In late 2024, Akari completed a transformational merger with Peak Bio, Inc., approved by shareholders on November 7 and closed around November 13, creating a combined entity with expanded resources for ADC and geographic atrophy platforms while addressing Nasdaq compliance; this followed a March 2024 definitive agreement and narrowed pipeline focus, with 2024 financials reflecting renewed emphasis on AKTX-101 preclinical data expected in late 2025.
Company News
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Akari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
Why Akari Therapeutics Stock Is Falling On Tuesday?
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models